Orthopedics and Traumatology, Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Demetevler Mahallesi, Vatan Cad., Yenimahalle, 06200, Ankara, Turkey.
Orthopedics, Rothman Orthopedic Institute at Thomas Jefferson University Hospital, Philadelphia, PA, USA.
Clin Transl Oncol. 2024 Feb;26(2):524-531. doi: 10.1007/s12094-023-03273-8. Epub 2023 Aug 3.
This study aims to investigate demographic data, survival rates, and the relationship of these rates with surgery in a large case series including multiple myeloma (MM) patients.
MM cases were analyzed retrospectively using the latest version of the SEER database published in April 2020. This version covers January 1975 to December 2017. Patients were classified according to gender, age, and race/ethnicity. Tumors were classified according to their localization, grade, year of diagnosis, and follow-up results.
There were 60,239 patients diagnosed with Plasma Cell Myeloma. While 670 patients (1.2%) were operated on, 43,976 patients (76.7%) did not indicate operation, and 12,670 patients (22.1%) could not be operated on despite the recommendation. The mean survival was 62 months in those without an indication for surgery, and 42 months in patients with an indication but could not be operated on, and the difference was significant (p = 0.001). The mean survival was 58 months in the operated patients, and 42 months in the patients who could not be operated on despite the indication, and the difference was significant (p = 0.001). There was no difference between those who did not indicate surgery and those who were operated on with an indication (p = 0.243).
In multiple myeloma, the best prognosis is in the group of patients who received medical treatments without any indication for operation, while an indication for operation indicates a worse prognosis. A worse prognosis should be expected in patients who do not accept the operation or who cannot be operated on compared to the operated patients.
本研究旨在通过最新版本的 SEER 数据库(2020 年 4 月发布),分析包括多发性骨髓瘤(MM)患者在内的大量病例系列的人口统计学数据、生存率以及这些数据与手术的关系。
使用最新版本的 SEER 数据库(2020 年 4 月发布)对 MM 病例进行回顾性分析。该版本涵盖了 1975 年 1 月至 2017 年 12 月的数据。根据性别、年龄和种族/民族对患者进行分类。根据肿瘤定位、分级、诊断年份和随访结果对肿瘤进行分类。
共诊断出 60239 例浆细胞骨髓瘤患者。670 例(1.2%)接受了手术,43976 例(76.7%)未表明手术,12670 例(22.1%)尽管建议手术但无法手术。无手术指征患者的平均生存期为 62 个月,有手术指征但无法手术的患者为 42 个月,差异有统计学意义(p=0.001)。手术患者的平均生存期为 58 个月,有手术指征但无法手术的患者为 42 个月,差异有统计学意义(p=0.001)。无手术指征与有手术指征且接受手术的患者之间无差异(p=0.243)。
在多发性骨髓瘤中,最佳预后是在未接受任何手术指征治疗的患者中,而手术指征则预示着预后更差。与接受手术的患者相比,不接受手术或无法手术的患者预后更差。